Mass Spectrometry Experts on E&L Testing: Ensuring Device and Packaging Safety 

E&L Testing Mass Spectrometry Expertsv

Introduction

In the pharmaceutical and medical device industry, E&L Testing Mass Spectrometry Experts are essential for keeping patients safe, ensuring regulatory compliance, and maintaining product quality. Extractables and Leachables (E&L) testing identifies chemicals that may move from packaging or device components into medicines or biologics. At ResolveMass Laboratories Inc., our specialists use advanced mass spectrometry tools to deliver highly accurate and reliable results. With deep regulatory knowledge and modern technology, we support manufacturers in meeting strict global requirements while protecting patients from hidden risks. This careful approach helps ensure both safety and long-term product performance.

👉 Ready to safeguard your products with expert testing?

Connect with our team of E&L Testing Mass Spectrometry Experts today and ensure your devices and packaging meet the highest safety and regulatory standards.

Summary of Key Insights

  • E&L Testing Mass Spectrometry Experts ensure device and packaging safety.
  • Extractables (compounds extracted under stress) and Leachables (compounds migrating during shelf life) must be monitored to meet global regulatory standards.
  • Mass spectrometry provides unmatched sensitivity and accuracy in detecting extractables and leachables.
  • ResolveMass Laboratories Inc. offers advanced E&L testing services with deep expertise in bioanalytical quantificationPFAS testingresidual solvent testing, and more.
  • Compliance with FDA, EMA, and ICH guidelines requires robust testing strategies.
  • Trusted partnerships are key: ResolveMass guarantees high quality, regulatory adherence, and technical excellence.

Why E&L Testing Requires Mass Spectrometry Experts

E&L testing is not only about meeting regulations—it directly impacts the safety, quality, and effectiveness of medicines. Without accurate testing, contaminants such as heavy metals, nitrosamines, or phthalates can enter drug formulations, leading to serious risks for patients.

Our mass spectrometry experts add value by detecting compounds at extremely low levels, differentiating between extractables and true leachables, supporting toxicological risk assessments, and identifying unknown structures with precision. This expertise helps prevent recalls, ensures patient safety, and builds lasting trust in pharmaceutical products.

Extractables vs. Leachables: What You Need to Know

TermDefinitionWhy It Matters
ExtractablesSubstances released under strong lab conditions such as heat or solventsPredicts possible risks before they occur
LeachablesCompounds that move into the drug during actual storage or usageDirectly impacts patient safety and product stability

At ResolveMass, our specialists ensure that both extractables and leachables are fully studied and reported. This complete approach gives manufacturers and regulators the clarity needed to make informed decisions and avoid costly failures in later development stages.

Regulatory Requirements and the Role of Experts

Global agencies such as the FDA and EMA require strict E&L testing for packaging, biologics, and drug-device combinations. These rules demand advanced tools like LC-MS/MS, GC-MS, and HRMS, along with professionals who can interpret complex datasets.

ResolveMass Laboratories partners with pharma and biotech firms to navigate regulatory complexity by offering:

Core Capabilities of ResolveMass in E&L Testing

Our E&L Testing Mass Spectrometry Experts bring unmatched scientific knowledge and access to advanced infrastructure, including:

  • High-resolution systems such as Orbitrap, TOF-MS, and triple quadrupole platforms.
  • Specialized assays for proteomics, lipidomics, biomarker studies, and peptide characterization.
  • End-to-end project support, from early method development through regulatory submissions.
  • Experience across multiple therapeutic areas including vaccines, oncology, biologics, and complex drug-device systems.

This broad expertise ensures studies are reliable, compliant, and customized to the needs of each client.

Why Choose ResolveMass Laboratories?

Selecting the right partner for E&L testing has a direct impact on patient safety and regulatory outcomes. At ResolveMass Laboratories, our strengths include:

  • Experience: Specialized expertise in analytical chemistry and regulatory science.
  • Expertise: Highly trained scientists focused on E&L mass spectrometry and toxicology.
  • Credibility: A trusted partner recognized by pharma and medical device firms worldwide.
  • Compliance: GLP-certified labs and transparent, regulator-aligned methods.

This combination makes us a reliable partner for companies looking to safeguard products and speed up approvals.

Advanced Applications of Mass Spectrometry in E&L Studies

  1. Nitrosamine Detection
  2. Residual Solvent Testing
  3. Pesticide Screening for Raw Materials
  4. Specialized Omics Platforms

Conclusion

The role of E&L Testing Mass Spectrometry Experts is vital in safeguarding patients, meeting regulations, and ensuring product quality. As drug-device systems become more advanced, the need for accurate analytical testing only grows stronger.

ResolveMass Laboratories Inc. is proud to lead in this space, offering services such as extractables and leachables testing, nitrosamine analysis, PFAS detection, solvent studies, and advanced proteomics. With experienced scientists and cutting-edge tools, we deliver the accuracy and trust companies need to succeed.

Start your projectContact us

Get In Touch With Us

About The Author

References

  1. Martins, D. N., Vendramini, P. H., Simionato, A. V. C., & Sussulini, A. (2022). Introduction to bioanalytical mass spectrometry. In L. T. Kubota, J. A. F. da Silva, M. M. Sena, & W. A. Alves (Eds.), Tools and trends in bioanalytical chemistry (pp. 317–338). Springer. https://doi.org/10.1007/978-3-030-82381-8_23
  2. Klont, F., & Hopfgartner, G. (2021). Mass spectrometry-based approaches and strategies in bioanalysis for qualitative and quantitative analysis of pharmaceutically relevant molecules. Drug Discovery Today: Technologies, 40, 64–68. https://doi.org/10.1016/j.ddtec.2021.10.004
  3. Rathore, D., Schiel, J. E., Faustino, A., Pang, E., Boyne, M., & Rogstad, S. M. (2018). The role of mass spectrometry in the characterization of biologic protein products. Expert Review of Proteomics, 15(5), 431–449. https://doi.org/10.1080/14789450.2018.1469982

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
Review Your Cart
0
Add Coupon Code
Subtotal